SARS-CoV-2 (COVID-19) vaccine 2023-2024, mRNA-BNT162b2 OMICRON (XBB.1.5) 0.3 mL Prefilled Syringe, 12y+
RxNorm 2664837

Concept Hierarchy & Relationship Mapping

RxNorm Concept Unique Identifier (RxCUI) 2664837 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: SARS-CoV-2 (COVID-19) vaccine 2023-2024, mRNA-BNT162b2 OMICRON (XBB.1.5) 0.3 mL Prefilled Syringe, 12y+.

The following semantic concepts and normalized strings are associated with this clinical entity:

SCD
0.3 mL SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 OMICRON (XBB.1.5) 0.1 mg/ML Prefilled Syringe
Primary clinical definition
AUI:12852218
View
PSN
SARS-CoV-2 (COVID-19) vaccine 2023-2024, mRNA-BNT162b2 OMICRON (XBB.1.5) 0.3 mL Prefilled Syringe, 12y+
AUI:12852227
View
SY
SARS-CoV-2 (COVID-19) vaccine 2023-2024, mRNA-BNT162b2 OMICRON (XBB.1.5) 0.3 mL Prefilled Syringe, 12y+
AUI:12852226
View

This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.

SCD

Semantic Clinical Drug (SCD):
0.3 mL SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 OMICRON (XBB.1.5) 0.1 mg/ML Prefilled Syringe
(Atom ID: 12852218)

Clinical Status & Identity

Prescribable Status
NO (Reference)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
0.3 ML SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 OMICRON (XBB.1.5) 0.1 MG/ML Prefilled Syringe
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
2664837
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
12852218
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
SCD
Semantic Clinical Drug (Ingredient + Strength + Dose Form)
Source Code
2664837
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

Technical Attributes & Logic

RXN AI
{2664835} 2664825
RXCUI of BOSS Active Ingredient preceded by RXCUI of SCDC responsible for value
RXN AM
{2664835} 2468231
RXCUI of BOSS Active Moiety preceded by RXCUI of SCDC responsible for value
RXN BOSS FROM
{2664835} AI
Source of BOSS as either from the active ingredient (AI) or the active moiety (AM) preceded by RXCUI of SCDC responsible for value
RXN QUANTITY
0.3 ML
Normal Form quantity factor
RXTERM FORM
Prefilled Syringe
The RxTerm dose form name for this drug
PSN

Prescribable Name (PSN):
SARS-CoV-2 (COVID-19) vaccine 2023-2024, mRNA-BNT162b2 OMICRON (XBB.1.5) 0.3 mL Prefilled Syringe, 12y+
(Atom ID: 12852227)

Clinical Status & Identity

Prescribable Status
NO (Reference)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
SARS-CoV-2 (COVID-19) vaccine 2023-2024, mRNA-BNT162b2 OMICRON (XBB.1.5) 0.3 ML Prefilled Syringe, 12y+
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
2664837
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
12852227
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
PSN
Prescribable Name (Synonym of another TTY, given for clarity and for display purposes in electronic prescribing applications. Only one PSN per concept.)
Source Code
2664837
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.
SY

Synonym (SY):
SARS-CoV-2 (COVID-19) vaccine 2023-2024, mRNA-BNT162b2 OMICRON (XBB.1.5) 0.3 mL Prefilled Syringe, 12y+
(Atom ID: 12852226)

Clinical Status & Identity

Prescribable Status
NO (Reference)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
SARS-CoV-2 (COVID-19) vaccine 2023-2024, mRNA-BNT162b2 OMICRON (XBB.1.5) 0.3 ML Prefilled Syringe, 12y+
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
2664837
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
12852226
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
SY
Synonym (Synonym of another TTY, given for clarity.)
Source Code
2664837
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

Patient Education

COVID-19 Vaccine, mRNA


Why get vaccinated? COVID-19, mRNA vaccine can prevent COVID-19 disease. COVID-19 disease is caused by a coronavirus called SARS-CoV-2. You can get COVID-19 through contact with another person who has the virus. It is predominantly a respiratory (lung) illness, but it can also affect other organs. People with COVID-19 have had a wide range of symptoms reported, ranging from mild symptoms to severe illness leading to death. Symptoms may appear 2 to 14 days after exposure to the virus. Symptoms may include: fever, chills, cough, shortness of breath, fatigue, muscle or body aches, headache, loss of taste or smell, sore throat, congestion, runny nose, nausea, vomiting, or diarrhea.
[Learn More]


COVID-19 Vaccines


COVID-19 (coronavirus disease 2019) is an illness caused by a virus. This virus is a coronavirus called SARS-CoV-2. In the United States, there are several vaccines that are effective at protecting people from getting seriously ill, being hospitalized, and dying from COVID-19. These vaccines are being used under Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA). This means that the vaccines have met the FDA's scientific standards for safety, effectiveness, and manufacturing quality that are needed to support authorization.

This page includes details about the vaccines and the vaccination program, including where you can find a vaccine.

Centers for Disease Control and Prevention


[Learn More]


* Please review the disclaimer below.